Sorrento Therapeutics : November 2021 Corporate Presentation

November 2021

NASDAQ: SRNE

©2021 Sorrento Therapeutics, Inc. All Rights Reserved

SORRENTO THERAPHEUTICS

Forward-Looking Statements and Non-GAAP Financial Information

Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the "Company" or "Sorrento") and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, are or may be considered "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate," "potential," "projected" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. Sorrento cautions that these statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA's or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company's formulations and products and regulatory filings related to the same, and receipt by the Company of milestone and royalty payments may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors"set forth in those filings.

In presenting this material or responding to inquiries in connection with a presentation, management may refer to results, projections or performance measures that are not prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") as reported in the Company's SEC filings. These results, projections or performance measures are non-GAAP measures and are not intended to replace or substitute for results measured under GAAP and are supplemental to GAAP reported results.

Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its SEC filings on Forms 10-K,10-Q and 8-K, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are advised to consult the Company's filings for a more complete listing of risk factors, contingencies and uncertainties affecting the Company and its business and financial performance.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

© 2021 Sorrento Therapeutics, Inc. All Rights Reserved

About Us

• Funded and Operational in 2009.
• NASDAQ: SRNE.
• HQ in San Diego, CA.

~750 Employees worldwide.

~120 Employees with PhDs & MDs.

~500,000 SF Research and cGMP Manufacturing Facilities.

• 7 cGMP Manufacturing Sites (5 USA, 2 China).

mAbs, Small Molecule, ADC, Plasmid DNA, Lymphatic Drug Delivery Device,

Cell Therapies, Oncolytic Viruses, and Fill & Finish.

• 1 FDA Approved Drug.

ZTlido® (lidocaine topical system) 1.8%.

• Multiple Products in Late-Stage Clinical Development.

Focused on Pain Management, Immune-Oncology and COVID-19.

© 2021 Sorrento Therapeutics, Inc. All Rights Reserved

SORRENTO THERAPEUTICS

Transforming GMAB Innovative Platforms into Saving Life™ Medicines

© 2021 Sorrento Therapeutics, Inc. All Rights Reserved

THERAPEUTIC AREAS OF FOCUS

CANCER	AUTOIMMUNE	COVID-19	NON-OPOID PAIN
Abivertinib	Abivertinib	COVISTIX1	2
CD38 DAR-T	COVITRACK	ZTlido 1.8%
	SP-102
CD38 ADC
	COVI-AMG	SP-103 (ZTlido 5.4%)
CD47 mAb		COVDROPS	SP-104
PD-L1 mAb
	COVISHIELD	Resiniferatoxin (RTX)
Trop2 ADC
	Abivertinib
Bevacizumab ADNAB
		COVI-MSC
			1 Marketed product in Mexico
			2 Marketed product

© 2021 Sorrento Therapeutics, Inc. All Rights Reserved